FDA-Inspected Site

Eurofins BioPharma Product Testing Toronto, Inc.

6 FDA inspections are on record for Eurofins BioPharma Product Testing Toronto, Inc. in North York, Canada.

Clean· No action indicated

North York, Canada · Last updated July 10, 2026

Overview

  • 6 FDA inspections are on record.
  • 2 inspections produced a Form 483.
  • The most recent recorded inspection date is 2023-11-15.

At a glance

Inspections

6

Form 483s

2

EIRs

0

Last outcome

Clean

Inspection history

FDA inspections on record, most recent first.

InspectionCategoryOutcomeForm 483
13 Nov 2023 – 15 Nov 2023Human DrugsClean
12 Nov 2019 – 15 Nov 2019Human Drugs483View 483 →
17 Feb 2016 – 19 Feb 2016Human DrugsClean
27 Mar 2012Not recordedClean
18 Jul 2008Not recorded483On file
7 Apr 2000Not recordedClean

Observations on record

Form 483 observations cited at this site, most recent first.

15 Nov 2019
21 CFR 211.192

Written record of investigation incomplete

Cited by Arsen Karapetyan

15 Nov 2019
21 CFR 211.192

Written record of investigation incomplete

Cited by Arsen Karapetyan

15 Nov 2019
21 CFR 211.194(a)

Complete test data included in records

Cited by Arsen Karapetyan

15 Nov 2019
21 CFR 211.194(a)

Complete test data included in records

Cited by Arsen Karapetyan

15 Nov 2019
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Arsen Karapetyan

Investigators

FDA investigators tied to this site in the record.

Recurring citations

CFR citation patterns observed across this site's inspections.

CitationWhat it coversCited
21 CFR 211.192Cited across public-safe Form 483 observations2x
21 CFR 211.194(a)Cited across public-safe Form 483 observations2x
21 CFR 211.22(d)Cited across public-safe Form 483 observations2x

Full site report

Get the verbatim findings behind Eurofins BioPharma Product Testing Toronto, Inc.'s 2 Form 483s

Source PDFs and recurring CFR citations, so your team knows what this site gets cited for.

  • The site's full inspection history, with every Form 483 and its outcome
  • Warning letters and recalls tied to the company behind it
  • Whether recurring CFR citations get closed out or repeat